Format

Send to

Choose Destination
Expert Opin Drug Deliv. 2013 Feb;10(2):273-83. doi: 10.1517/17425247.2013.746311. Epub 2012 Dec 20.

RebiSmart™ (version 1.5) device for multiple sclerosis treatment delivery and adherence.

Author information

1
Department of Neuroscience and Imaging, University G. d'Annunzio, c/o Centro Sclerosi Multipla, Ospedale Clinicizzato SS Annunziata, Via dei Vestini 31, 66100 Chieti, Italy. a.lugaresi@unich.it

Abstract

INTRODUCTION:

First-line disease-modifying drugs for the treatment of multiple sclerosis (MS) are mostly administered by injection. Although these treatments can control the symptoms and progression of the disease to some extent, patients often fail to adhere to their therapy in the long term, so may not obtain the maximum clinical benefits. As injection-related problems are common barriers to adherence, autoinjectors have been developed to improve the ease and convenience of self-injection.

AREAS COVERED:

This article discusses RebiSmart™, an electronic autoinjector for the subcutaneous administration of interferon β-1a, focusing on the device features and data from clinical trials of the device. An overview of other available autoinjectors for first-line MS therapies is provided for context.

EXPERT OPINION:

The device is the first electronic autoinjector for use in MS and offers several innovative features, including adjustable injection settings and an electronic dosing log, which may improve adherence. The dosing log can be reviewed with the patient, allowing the physician to open a dialogue to discuss possible issues with treatment adherence. The use of multidose cartridges also provides a softer impact on the environment and easier disposal. The hidden needle helps avoid needle phobia and reduces the risk of needle stick injury.

PMID:
23252744
DOI:
10.1517/17425247.2013.746311
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center